Diferencia entre revisiones de «Template:Pyelonephritis antibiotics»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 1: | Línea 1: | ||
===Outpatient=== | ''Treatment is targeted at [[E. coli]], [[Enterococcus]], [[Klebsiella]], [[Proteus]], [[S. saprophyticus]]'' | ||
====Outpatient==== | |||
''Give one dose of [[Ceftriaxone]] 1g IV or [[Gentamycin]] 7mg/kg IV if the regional susceptibility of [[TMP/SMX]] or [[Fluoroquinolones]] is < 80% | |||
*[[Ciprofloxacin]] 500mg BID x 7 days OR | |||
*[[ | *[[Cefpodoxime]] 200 mg BID x10-14 days OR<ref>Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.</ref> | ||
===Inpatient Options=== | *[[Levofloxacin]] 750mg PO once x 7 days<ref>Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.</ref> | ||
====Inpatient Options==== | |||
*[[Ciprofloxacin]] 400mg IV q12hr OR | *[[Ciprofloxacin]] 400mg IV q12hr OR | ||
*[[Ceftriaxone]] 1gm IV QD OR | *[[Ceftriaxone]] 1gm IV QD OR | ||
Revisión del 16:13 20 abr 2015
Treatment is targeted at E. coli, Enterococcus, Klebsiella, Proteus, S. saprophyticus
Outpatient
Give one dose of Ceftriaxone 1g IV or Gentamycin 7mg/kg IV if the regional susceptibility of TMP/SMX or Fluoroquinolones is < 80%
- Ciprofloxacin 500mg BID x 7 days OR
- Cefpodoxime 200 mg BID x10-14 days OR[1]
- Levofloxacin 750mg PO once x 7 days[2]
Inpatient Options
- Ciprofloxacin 400mg IV q12hr OR
- Ceftriaxone 1gm IV QD OR
- Cefotaxime 1-2gm IV q8hr OR
- Gentamicin 3mg/kg/day divided q8hr +/- ampicillin 1–2 gm q4hr OR
- Piperacillin/Tazobactam 3.375 gm IV q6hr OR
- Cefepime 2gm IV q8hr OR
- Imipenem 500mg IV q8hr
- ↑ Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.
- ↑ Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.